A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin’s lymphoma - Cooney-Qualter, E; Krailo, M; Angiolillo, A (Clin Cancer Res, 2007)
et al.